About the Company
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRTA News
Prothena Appoints David Ford to Newly Created Chief People Officer Position
DUBLIN, March 04, 2024--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein ...
Prothena Plc (NASDAQ: PRTA)
Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical ...
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript
Prothena Corporation plc misses on earnings expectations. Reported EPS is $-1.26 EPS, expectations were $-1.23. PRTA isn't one of the 30 most popular stocks among hedge funds at the end of the ...
PRTA Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company ...
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
It had no debt as of the same date. Prothena Corporation plc Price, Consensus and EPS Surprise Revenues in 2023 totaled $91.4 million, up from $53.9 million in 2022. The figure, however ...
Prothena Corp PLC PRTA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported ...
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Prothena Corporation plc (NASDAQ:PRTA) is gearing up to report an update on its ongoing phase 1 study, using PRX012 for the treatment of patients with Alzheimer's Disease [AD]. It is expected that ...
Prothena to Participate in Upcoming Healthcare Conferences
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...
Prothena to Participate in Jefferies 2023 Healthcare Conference
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...
Prothena Corp PLC PRTA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Prothena Corporation plc
Analysts say these cheap stocks have plenty of upside.
Loading the latest forecasts...